Days
Hours
Minutes
Seconds
-40%
on all subscriptions*
Last hours
Enjoy this offer
* See conditions under "Our services"

Valuation: Insulet Corporation

Market Cap 10.1B 8.8B 8.14B 7.63B 14.29B 952B 14.4B 96.66B 37.45B 469B 37.89B 37.08B 1,628B P/E 2026 *
23.5x
P/E 2027 * 18.3x
Enterprise Value 10.18B 8.87B 8.21B 7.69B 14.4B 960B 14.52B 97.43B 37.75B 472B 38.2B 37.38B 1,641B EV / Sales 2026 *
3.06x
EV / Sales 2027 * 2.49x
Free-Float
97.63%
Yield 2026 *
-
Yield 2027 * -

Last Transcript: Insulet Corporation

1 day+1.56%
1 week-2.63%
Current month+0.57%
1 month-5.72%
3 months-36.25%
6 months-49.67%
Current year-48.72%
1 week 142.1
Extreme 142.103
150.89
1 month 140.63
Extreme 140.63
161.35
Current year 140.63
Extreme 140.63
299.8
1 year 140.63
Extreme 140.63
354.88
3 years 125.82
Extreme 125.82
354.88
5 years 125.82
Extreme 125.82
354.88
10 years 27.62
Extreme 27.6201
354.88
Manager TitleAgeSince
Chief Executive Officer 55 2025-04-27
Director of Finance/CFO 53 2025-09-29
Compliance Officer 50 2022-11-30
Director TitleAgeSince
Chairman 61 2018-12-31
Director/Board Member 61 2015-07-26
Director/Board Member 59 2017-08-09
Date Insider Type Main position Quantity % Market Cap.
06-02Buy

Director

3,450 0.0049%
06-02Buy

Director

2,790 0.0040%
06-02Sell

Director

-418 0.0006%
Change 5-day change 1-year change 3-year change Capi.($)
+1.56%-2.63%-51.70%-48.77% 10.1B
-0.10%+0.26%-33.23%-16.75% 154B
+1.54%-1.07%-7.45%-11.00% 102B
-4.45%+3.12%+59.84%+56.09% 56.51B
-1.90%-3.49%-8.40%+48.53% 52.89B
+1.67%-1.55%-14.60%-44.33% 39.67B
-1.32%-1.83% - - 30.39B
+1.74%-3.85%-10.54%-44.30% 27.96B
+1.35%-0.26%+50.47%-9.42% 23.17B
-1.53%+1.14%-15.03%-5.42% 20.35B
Average -0.14%-1.40%-3.40%-8.37% 51.69B
Weighted average by Cap. -0.23%-1.26%-7.13%-3.66%

Financials

2026 *2027 *
Net sales 3.32B 2.9B 2.68B 2.51B 4.7B 313B 4.74B 31.82B 12.33B 154B 12.47B 12.2B 536B 3.94B 3.43B 3.17B 2.98B 5.57B 371B 5.62B 37.69B 14.6B 183B 14.78B 14.46B 635B
Net income 432M 377M 348M 327M 611M 40.75B 616M 4.14B 1.6B 20.06B 1.62B 1.59B 69.69B 565M 493M 456M 427M 800M 53.29B 806M 5.41B 2.1B 26.24B 2.12B 2.08B 91.13B
Net Debt 80.64M 70.31M 65.02M 60.94M 114M 7.6B 115M 772M 299M 3.74B 303M 296M 13B -289M -252M -233M -218M -409M -27.23B -412M -2.76B -1.07B -13.41B -1.08B -1.06B -46.57B
Logo Insulet Corporation
Insulet Corporation specializes in the design, manufacture and marketing of medical devices intended to improve the lives of people with insulin-dependent diabetes. In addition, the group offers non-insulin subcutaneous drug delivery systems used in several therapeutic areas. Net sales break down by family of products as follows: - Insulin pump therapy systems (98.7%): continuous insulin management and delivery systems (Omnipod® and Omnipod DASH® brands) and automated insulin administration systems (Omnipod® 5 brand); - non-insulin drug administration systems (1.3%): in particular pre-filled syringes for the Neulasta® Onpro® kit (intended for the treatment of neutropenia in patients treated with chemotherapy). At the end of 2025, the group had 2 production sites located in the United States and in China. The United States account for 72.2% of net sales.
Employees
5,400
Date Price Change Volume
26-06-18 145.76 $ +1.56% 2,864,144
26-06-17 143.52 $ -2.82% 1,542,221
26-06-16 147.69 $ -0.30% 942,276
26-06-15 148.14 $ -1.04% 1,041,258
26-06-12 149.70 $ +0.34% 992,614
Trader
Investor
Global
Quality
ESG MSCI
A
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
24
Last Close Price
145.76USD
Average target price
242.43USD
Spread / Average Target
+66.32%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. PODD Stock
LAST HOURS | 40% Discount: The Best Subscriber-Only Tools to Unlock Hidden Opportunities!
d
:
:
SEIZE THE OFFER!